drugset
drugset / Trial / NCT04599543

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

NCT04599543 ↗

Phase 0 Not yet recruiting 36 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.

Timeline

Start
2020-11-15
Primary completion
2023-11-15
Completion
2026-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject IL3 CAR T-cells Cell therapy — Intravenous

Indications

acute myeloid leukemia